screenshot of video for Heath PACT

How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells
How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells
Glioblastoma tumor slice and corresponding density map

Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy

To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.

Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy
Looking at Tumors Through a New Lens: New Research May Improve Efficacy of Glioblastoma Immunotherapy
Dr. Wei Wei and Dr. Xiaowei Yan

A Better Way to Find Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients

Despite the aggressive nature of Non-Small Cell Lung Cancer (NSCLC), circulating tumor cells that lead to metastases often go undetected in the blood. ISB researchers in Dr. Wei Wei’s lab and their collaborators have developed a novel method to better detect these circulating cells.

A Better Way to Find Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients
A Better Way to Find Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients
CRI iAtlas banner

CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors. 

CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments
CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments
Corresponding author and ISB President Dr. Jim Heath and lead author Dr. Yapeng Su.

For Cancer Cells, There Is More Than One Path to Drug Resistance

In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

For Cancer Cells, There Is More Than One Path to Drug Resistance
For Cancer Cells, There Is More Than One Path to Drug Resistance
1 2